Review
. 2020 Apr 14;26(14):1546-1553. doi: 10.3748/wjg.v26.i14.1546. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultantAffiliations
AffiliationsItem in Clipboard
Review
SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultantKaveh Hajifathalian et al. World J Gastroenterol. 2020.
. 2020 Apr 14;26(14):1546-1553. doi: 10.3748/wjg.v26.i14.1546. AffiliationsItem in Clipboard
AbstractThe current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally, and the number of cases is expected to continue to increase, at least in the immediate future. The virus is estimated to have infected more than 1.5 million individuals. The available reports suggest that gastrointestinal (GI) involvement in coronavirus disease 2019 (COVID-19) is common and in some cases the GI symptoms may precede the respiratory symptoms. In addition to direct effects of severe acute respiratory syndrome coronavirus 2, the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants. The most commonly reported GI manifestation of COVID-19 is diarrhea, which is reported in a third to up to more than half of the patients. Mild to moderate elevation of the liver enzymes are also common, although no case of acute liver failure has been reported so far. Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients. Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples, the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test. It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus.
Keywords: COVID-19; Gastroenterology; Hepatology; Liver; SARS-CoV-2.
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statementConflict-of-interest statement: The authors declare that they have no conflict of interest.
Similar articlesParasa S, Desai M, Thoguluva Chandrasekar V, Patel HK, Kennedy KF, Roesch T, Spadaccini M, Colombo M, Gabbiadini R, Artifon ELA, Repici A, Sharma P. Parasa S, et al. JAMA Netw Open. 2020 Jun 1;3(6):e2011335. doi: 10.1001/jamanetworkopen.2020.11335. JAMA Netw Open. 2020. PMID: 32525549 Free PMC article.
Ferm S, Fisher C, Pakala T, Tong M, Shah D, Schwarzbaum D, Cooley V, Hussain S, Kim SH. Ferm S, et al. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2378-2379.e1. doi: 10.1016/j.cgh.2020.05.049. Epub 2020 Jun 1. Clin Gastroenterol Hepatol. 2020. PMID: 32497637 Free PMC article.
Keshta AS, Mallah SI, Al Zubaidi K, Ghorab OK, Keshta MS, Alarabi D, Abousaleh MA, Salman MT, Taha OE, Zeidan AA, Elsaid MF, Tang P. Keshta AS, et al. J Infect Public Health. 2021 Jul;14(7):967-977. doi: 10.1016/j.jiph.2021.04.007. Epub 2021 Apr 24. J Infect Public Health. 2021. PMID: 34130121 Free PMC article. Review.
Roychoudhury S, Das A, Sengupta P, Dutta S, Roychoudhury S, Choudhury AP, Ahmed ABF, Bhattacharjee S, Slama P. Roychoudhury S, et al. Int J Environ Res Public Health. 2020 Dec 15;17(24):9411. doi: 10.3390/ijerph17249411. Int J Environ Res Public Health. 2020. PMID: 33333995 Free PMC article. Review.
Andrews PLR, Cai W, Rudd JA, Sanger GJ. Andrews PLR, et al. J Gastroenterol Hepatol. 2021 Mar;36(3):646-656. doi: 10.1111/jgh.15261. Epub 2020 Oct 5. J Gastroenterol Hepatol. 2021. PMID: 32955126 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3